Highlights from the 2016 WIN Symposium, 27-29 June 2016, Paris: personalised therapy beyond next-generation...

Area of Science:

• Oncology
• Genomic Medicine
• Clinical Trials

Background:

• The Worldwide Innovative Networking (WIN) consortium fosters global collaboration in cancer research.
• WIN aims to improve patient outcomes through genomic-based medicine and open dialogue.

Purpose of the Study:

• To discuss recent advances in personalized medicine and genomic analysis.
• To share clinical trial results and new developments in cancer therapeutics.

Main Methods:

• Annual WIN Symposium featuring dedicated sessions, debates, and poster presentations.
• Discussion of clinical trials such as MINDACT and SHIVA.
• Exploration of liquid biopsy applications for real-time tumor profiling.

Main Results:

• MINDACT trial demonstrated gene expression tests can identify breast cancer patients who can avoid chemotherapy.
• SHIVA trial reflections provided insights into treatment strategies.
• Liquid biopsies offer rapid insights into tumor mutational profiles.

Conclusions:

• Genomic analysis and personalized medicine are crucial for advancing cancer care.
• Liquid biopsies represent a significant development in real-time tumor monitoring.
• Collaboration through consortia like WIN accelerates therapeutic innovation.